GRI Bio Announces Phase 2a Translational Biomarker Data

What Happened

• GRI Bio, Inc. (GRI) filed a Current Report on Form 8‑K on September 8, 2026 disclosing an updated corporate presentation and issuing a press release announcing new translational biomarker data from its Phase 2a study of GRI‑0621 (oral tazarotene) in patients with idiopathic pulmonary fibrosis (IPF). The presentation was posted to the company’s investor website and included as Exhibit 99.1; the press release is Exhibit 99.2 to the 8‑K. The filing was signed by CFO Leanne Kelly.

Key Details

• Filing date: September 8, 2026 (Form 8‑K, Items 7.01 and 8.01).
• Program: GRI‑0621 (oral tazarotene) being evaluated in a Phase 2a clinical study for idiopathic pulmonary fibrosis (IPF).
• Materials posted: updated corporate presentation (Exhibit 99.1) and press release with biomarker data (Exhibit 99.2) on the company’s investor presentations page.
• Regulatory note: disclosure made under Regulation FD (Item 7.01) and the press release reported as an Other Event (Item 8.01).

Why It Matters

• Translational biomarker data can be an important clinical readout that informs whether a drug is having its intended biological effect; for investors, positive or clarifying biomarker results may serve as a near‑term scientific milestone and potential value catalyst for the GRI‑0621 program. This 8‑K does not report financial results or claim regulatory approvals; investors should review the posted presentation and press release for the detailed data and await additional clinical updates or company guidance.